NCT00192231View on ClinicalTrials.gov

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T)

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 30, 2001

Study Completion Date

June 30, 2001

Conditions
Influenza
Interventions
BIOLOGICAL

CAIV-T

Trial Locations (1)

3084

Austin & Repatriation Medical Centre, Heidelburg

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

MedImmune LLC

INDUSTRY

NCT00192231 - Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine,(CAIV-T) | Biotech Hunter | Biotech Hunter